Cutaneous melanoma · line 2 · Relatlimab + nivolumab (Opdualag, melanoma)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-RELATLIMAB-NIVOLUMAB-MELANOMA`

ID	`IND-MELANOMA-2L-RELATLIMAB-NIVOLUMAB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-MELANOMA`
Sources	`SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025` `SRC-RELATIVITY-047-TAWBI-2022`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 2L IO alternative for BRAF V600+ patients who received 1L BRAFi+MEKi (visceral crisis / brain mets indication) and need IO at 2L but cannot tolerate ipi+nivo. RELATIVITY was a 1L trial; 2L positioning is off-label / extrapolation — MDT documentation required. Ukraine access constraint dominant: relatlimab not registered (named-patient import only); fixed-dose Opdualag product unavailable without import.

Used By

Algorithms

ALGO-MELANOMA-METASTATIC-2L - ALGO-MELANOMA-METASTATIC-2L

Handbook Chapters

HB-MELANOMA-METASTATIC-1L - Metastatic melanoma: BRAF / IO first-line reasoning

Handbook Questions

HQ-MELANOMA-MET-1L-003 - HQ-MELANOMA-MET-1L-003